Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?

Zacks
在Zacks上打开
Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?

Lakefront Biotherapeutics - Sponsored ADR (LKFT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, LKFT's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."

There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typically, a golden cross involves the 50-day and the 200-day moving averages, since bigger time periods tend to form stronger breakouts.

A successful golden cross event has three stages. It first begins when a stock's price on the decline bottoms out. Then, its shorter moving average crosses above its longer moving average, triggering a positive trend reversal. The third and final phase occurs when the stock maintains its upward momentum.

A golden cross is the opposite of a death cross, another technical event that indicates bearish price movement may be on the horizon.

Shares of LKFT have been moving higher over the past four weeks, up 13.7%. Plus, the company is currently a #2 (Buy) on the Zacks Rank, suggesting that LKFT could be poised for a breakout.

Looking at LKFT's earnings expectations, investors will be even more convinced of the bullish uptrend. For the current quarter, there have been 1 change higher compared to none lower over the past 60 days, and the Zacks Consensus Estimate has moved up as well.

Moving Average Chart for LKFT

With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on LKFT for more gains in the near future.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Lakefront Biotherapeutics - Sponsored ADR (LKFT): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research